Home
HelpEpic Test Code LAB3813 Thiopurine Metabolites, Whole Blood
Additional Codes
MML:THIO
Ordering Guidance
This specimen cannot be shared with testing for tacrolimus, cyclosporine, sirolimus or everolimus. Testing for these must be ordered separately and separate specimens submitted.
Shipping Instructions
Specimen must be shipped refrigerated.
Specimen Required
Container/Tube: Lavender top (EDTA)
Specimen Volume: 3 mL
Collection Instructions: Send whole blood specimen in original tube. Do not aliquot, centrifuge, or freeze.
Useful For
Aids physicians in dose adjustments, minimizing dose-dependent toxicity, and monitoring compliance of thiopurine drug therapy
Testing Algorithm
A red blood cell (RBC) count is performed followed by determination of thiopurine metabolite values by liquid chromatography tandem mass spectrometry. Values are utilized to calculate and report the final results (unit of measure: pmol/8 x 10[8] RBC) for 6-thioguanine nucleotides and 6-methylmercaptopurine derivative analyte.
For more information see:
-Ulcerative Colitis and Crohn Disease Therapeutic Drug Monitoring Algorithm
-TPMT Testing in the Treatment of Inflammatory Bowel Disease Algorithm
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
Thiopurine Metabolites, BSpecimen Type
Whole Blood EDTASpecimen Minimum Volume
1.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole Blood EDTA | Refrigerated (preferred) | 8 days | |
| Ambient | 24 hours |
Reject Due To
| Gross hemolysis | Reject |
| Moderate hemolysis | Reject |
| Gross lipemia | OK |
| Gross icterus | OK |
| Clotted | Reject |
Clinical Information
This test is primarily used to verify compliance, optimize therapy, and identify elevated metabolite concentrations that may result in toxicity after initiation of thiopurine drug therapy for the treatment of inflammatory bowel disease. Recommended time points for monitoring include: 4 weeks after starting treatment to verify patient compliance and look for early risk of toxicity; 12 to 16 weeks after starting therapy when 6-thioguanine nucleotides have reached steady-state; and annually.(1) It may also be ordered in patients who do not respond to therapy as expected or as needed for dose changes, flare-ups, signs of toxicity, or suspicion of noncompliance. The test will measure 6-methylmercaptopurine and 6-thioguanine nucleotides in erythrocytes.
Reference Values
6-Thioguanine Nucleotides (6-TGN): 235-450 pmol/8x10(8) red blood cell (RBC)
6-Methylmercaptopurine (6-MMP): Less than or equal to 5700 pmol/8x10(8) RBC
Interpretation
Target 6-thioguanine concentrations are 235 to 450 pmol/8x10(8) red blood cell (RBC) with lower levels suggesting suboptimal dosing and higher levels associated with increased risk of myelotoxicity and leukopenia. High 6-methylmercaptopurine levels (greater than 5700 pmol/8x10[8] RBC) suggest an increased risk for hepatotoxicity and potentially "thiopurine hypermethylation."
Cautions
This test cannot be used to predict optimal starting dose. It is sensitive to hemolysis and transport conditions. This test does not replace monitoring of patients using other laboratory tests (eg, complete blood cell count, liver function tests).
Final concentrations are reported per the red blood cell (RBC) count (unit of measure =pmol/8 x 10[8] RBC) for the 6-thioguanine nucleotides and 6-methylmercaptopurine derivative analytes. Therefore, any significant lysis of the RBCs will lead to an artificially lower RBC count that could falsely increase the final concentrations. Due to this, moderately hemolyzed samples are rejected.
Day(s) Performed
Monday, Wednesday, Friday
Report Available
2 to 4 daysSpecimen Retention Time
14 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
80299NY State Approved
YesForms
If not ordering electronically, complete, print, and send Gastroenterology and Hepatology Test Request (T728) with the specimen